View Older Stories View More Recent Stories

Sep 16, 2020 07:32AM Arrowhead (ARWR) ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment
Sep 16, 2020 07:30AM Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment
Sep 8, 2020 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences
Sep 8, 2020 07:30AM Arrowhead Pharmaceuticals Appoints Oye Olukotun to Board of Directors
Aug 31, 2020 05:50AM Arrowhead Pharmaceuticals Inc. (ARWR) Highlights Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
Aug 31, 2020 04:50AM Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020
Aug 28, 2020 07:33AM Arrowhead (ARWR), Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress
Aug 28, 2020 07:30AM Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress
Aug 18, 2020 08:00AM Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences
Aug 18, 2020 07:32AM Arrowhead Pharmaceuticals Inc. (ARWR) Begins Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Aug 18, 2020 07:30AM Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Aug 11, 2020 07:34AM Arrowhead Pharmaceuticals Inc. (ARWR) Begins First Subject Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis
Aug 11, 2020 07:30AM Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis
Aug 5, 2020 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results
Jul 29, 2020 07:36AM Arrowhead Pharmaceuticals (ARWR) Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890
Jul 29, 2020 07:30AM Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890
Jul 28, 2020 11:59AM Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis
Jul 24, 2020 04:10PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Jul 9, 2020 07:30AM Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis
Jul 8, 2020 04:00PM Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Third Quarter Results
May 28, 2020 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming June 2020 Conferences
May 7, 2020 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2020 Second Quarter Results
May 1, 2020 04:00PM Arrowhead Pharmaceuticals Inc. (ARWR) Announces Retirement of COO Bruce Given
May 1, 2020 04:00PM Arrowhead Pharmaceuticals to Participate in Upcoming May 2020 Conferences
May 1, 2020 04:00PM Arrowhead Pharmaceuticals Announces Retirement of COO Bruce Given
Apr 22, 2020 07:30AM Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Second Quarter Results
Apr 13, 2020 06:02AM Arrowhead Pharmaceuticals Inc. (ARWR) Reports Regulatory Clearance to Begin Phase 1/2a Study of ARO-ENaC for Treatment of CF
Apr 10, 2020 07:30AM Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-ENaC for Treatment of Cystic Fibrosis
Mar 17, 2020 04:10PM Arrowhead Pharmaceuticals Announces Precautionary Measures to Mitigate Effects of Novel Coronavirus (COVID-19) Spread
Mar 17, 2020 04:10PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Mar 3, 2020 07:30AM Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH
Mar 2, 2020 04:00PM Arrowhead Pharmaceuticals to Participate in Upcoming March 2020 Conferences
Feb 5, 2020 04:00PM Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
Feb 5, 2020 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2020 First Quarter Results
Jan 22, 2020 07:30AM Arrowhead Pharmaceuticals to Webcast Fiscal 2020 First Quarter Results
Jan 6, 2020 07:30AM Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer
Dec 20, 2019 07:33AM Arrowhead Pharmaceuticals Inc. (ARWR) Reports First Patient Dosing in AROAAT2002 Open Label Phase 2 Study of ARO-AAT
Dec 20, 2019 07:30AM Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Dec 16, 2019 04:15PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Dec 16, 2019 07:32AM Arrowhead Pharmaceuticals Inc. (ARWR) Reports Filing for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD
Dec 16, 2019 07:30AM Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease
Dec 13, 2019 07:31AM Arrowhead Pharmaceuticals Inc. (ARWR) Announces Marianne De Backer to Board
Dec 13, 2019 07:30AM Arrowhead Pharmaceuticals Appoints Marianne De Backer to Board of Directors
Dec 11, 2019 07:31AM Arrowhead Pharmaceuticals Inc. (ARWR) Reports Filing of IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Dec 11, 2019 07:30AM Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Nov 26, 2019 04:00PM Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences
Nov 25, 2019 04:00PM Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results
Nov 18, 2019 09:32AM Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019
Nov 15, 2019 07:34AM Arrowhead (ARWR) announces Bruce Given, M.D., COO and head of R&D, plans to retire
Nov 15, 2019 07:30AM Arrowhead Pharmaceuticals Announces Planned Management Transition
View More Recent Stories View Older Stories